Comparative Pharmacology
Head-to-head clinical analysis: PENAPAR VK versus POLYCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENAPAR VK versus POLYCILLIN.
PENAPAR-VK vs POLYCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Polycillin (ampicillin) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6 hours; maximum 2 g/day.
250-500 mg orally every 6 hours or 500 mg intravenously every 4-6 hours for moderate to severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour in normal renal function; prolonged to 7–10 hours in severe renal impairment (anuria). Requires dose adjustment in renal failure.
Terminal elimination half-life is 0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in anuria.
Primarily renal excretion (tubular secretion) of unchanged drug (~90%); minor biliary/fecal elimination (<10%).
Renal excretion of unchanged drug accounts for 60-80% via glomerular filtration and tubular secretion; 20-40% is hepatically metabolized and eliminated in bile/feces.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic